SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LXII, Nr. 1, An 2013
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398

Indexed in / abstracted by

Thomson Reuters Embase
Scopus Cross-ref
Index Copernicus
Ulrichs Ebsco Host
Medline - Ebsco PubMed

HIGHLIGHTS

Publicarea de articole stiintifice

Stimati cititori, va reamintim ca autorii primi ai articolelor stiintifice pot acumula 80 de credite EMC in urma publicarii. Daca un articol are mai multi autori, cele 80 de credite [...]

Premiul Societatii pentru autori

Incepand cu 2016, Societatea Romana de Pediatrie ofera Premiul Societatii - pentru autorii celor mai bune articole stiintifice publicate [...]

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Ursodeoxycholic acid benefi t in pediatric non-alcoholic fatty liver disease

, , , , and

REZUMAT

Introduction. Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease in children, encompasses a range of disease from simple steatosis to steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been used in adult pacients with NASH, demonstrating its efficacy in high doses.

Purpose. The aim of our study was to assess the effect of high-dose ursodeoxycholic acid therapy on liver functions in children with NASH.

Methods. We prospectively studied 18 children with NASH aged 2.5 to 17 years. NASH was operationally defined as diffusely hyperechogenic liver at ultrasonography with persistently elevated (> 35 UI/l) alanine aminotransferase (ALT) or aspartate aminotransferaze (AST) after exclusion of viral, alcohol-induced, druginduced, cholestatic and genetic causes of liver disease. Patients were treated with ursodeoxycolic acid (20 mg/ kg per day) for six month.

Results. Treatment with UDCA significantly decreased hepatic transaminases. ALT levels ranged from 68.5 (50-166) at baseline vs. 47 (29-104) after six month, p <0.001, AST from 43 (29-101) 34 (17-75), p < 0.001, and GGT between 41.5 (11-150) vs. 22 (8-55). At the end of treatment, ALT levels normalized in 4 patients. Moreover, cholesterol levels were significantly reduced after treatment.

Conclusions. Treatment with high-dose ursodeoxycholic acid improves liver function parameters in children with NASH.

Cuvinte cheie: steatoză hepatică, acid ursodeoxicolic, transaminaze hepatice

Full text | PDF

Leave a Reply